Kenderick Lee was 24 and carving out a successful career in the corporate world when a diagnosis of the skin disease ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Investigators aimed to highlight aspects that may predict the time to relapse among patients with psoriasis who discontinued use of biologic therapy.

PD-1 and PD-L1 immune checkpoint inhibitors (ICIs) for treating advanced cancer were associated with an increased risk of new ...

Treatment persistence varied by biologic therapy use, sex, and diagnostic codes among patients with psoriasis.

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Biotech startup Evommune, an early tenant of the Kips Bay life sciences incubator known as Cure, raised $115 million in a ...

The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

Ixekizumab and apremilast may be an effective treatment among patients with genital psoriasis, with improved disease response and clearance rates.

The anti-IL-23 monoclonal antibody, called picankibart, was shown to clear or nearly clear all lesions after 16 weeks among 48.2% of the 82 participating Chinese patients that were classified as ...

Innovent Biologics (IVBXF) announced the latest clinical results of a multicenter, open-label Phase 2 study of picankibart, a recombinant ...

It's hard to imagine how much psoriasis affects patients' quality of life - especially if you are not affected yourself. But ...